Qureight, a life-sciences company which is supported by the Accelerate Cambridge programme at the Entrepreneurship Centre of Cambridge Judge Business School, announced a multi-year strategic collaboration on lung disease research with pharmaceutical firm AstraZeneca.
The collaboration allows AstraZeneca to use Qureight’s analytics platform and AI models to accelerate and improve research into multiple lung diseases, offering insight into how patients with complex lung diseases could respond to novel drugs.
“The multi-year collaboration announced today is an important validation of our technology stack and builds on our existing partnership with AstraZeneca, a leader in respiratory care,” said Dr Muhunthan Thillai, co-founder and CEO of Qureight, which was founded in Cambridge in 2018.
“We look forward to working closely with AstraZeneca in analysing data from patients with the fibrotic scarring lung IPF and other complex conditions.”
Related news
MFin student Justin Hyunjin Kim shares some of the highlights from his first few weeks on the Cambridge Master of Finance degree programme.
Programme news
How Cambridge collaboration spurs breakthroughs
An article in Nature on the Nobel-winning Laboratory of Molecular Biology began as a dialogue between a student and lecturer at the Executive MBA programme.
Student and alumni news
Wearable Scent Bubble® innovation wins grant
Scent Bubble®, a collaborative project between Sensory Design & Technology and Carolyn Mair Consulting Limited, has been awarded an Innovate UK Design Foundation grant. Dr Jenny Tillotson, founder of Sensory Design & Technology, is an alumna of Cambridge Judge Entrepreneurship Centre’s Accelerate Cambridge (2024).